Revefenacin Global Patent Coverage & Expiry Overview

Track protection status across key markets to assess launch feasibility.

Start your free 7-Day Trial! Book a demo to explore our global patent data.

It is formulated by 1 pharmaceutical company such as MYLAN IRELAND LTD. It is marketed under 1 brand name, including YUPELRI. Available in 1 different strength, such as 175MCG/3ML, and administered through 1 route including SOLUTION;INHALATION.

Strategic Dashboard

info

insightsStrategic Insights

Sourcing & Feasibility

check_circle API availability: autorenew Loading API feasibility...

groups Licensing: 1 potential partners

calendar_todayUS Launch window: autorenew Loading launch window...

timeline Key Patent Barrier & Expiry Timeline

autorenew Loading patent barriers...

factoryGeneric Manufacturer Snapshot

autorenew Loading manufacturers...

gavelRisk & Opportunity Summary

dangerous Risk: autorenew Loading risk analysis...
watch_later Watch: autorenew Loading watch analysis...
rocket_launch Opportunity: autorenew Loading opportunity analysis...
flag
gavel
calendar_today
calendar_today

Access Global Patent Data

Stay ahead with worldwide patent expiry and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patents

Orange Book Drug Approval Timeline

FDA approval history for this ingredient

NDA (New Drug Application) ANDA (Generic Application)

Access Global Exclusivity and Patent Expiry Extensions

Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
✓ Latest exclusivity data and extensions
Unlock Global Access

US Orange Book Patents Expiration Timeline

Key expiration dates for US patents covering this ingredient

View Global Patents Expiration Timeline

Stay ahead with worldwide patent expiry insights, market data, and research updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patent Timeline

Orange Book Drug Strengths

Latest drug strengths approved by FDA

Strength Route of Administration Companies Latest Approval Date

Orange Book Patents

Patents approved by the FDA for the ingredient

Patent Number Publication Date Legal Status Patent Expiry Date
{"application_id":"71297","ingredient":"REVEFENACIN","trade_name":"YUPELRI","family_id":"a6fff3d938544a1ba92e","publication_number":"US7491736B2","cleaned_patent_number":"7491736","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2025-03-10","publication_date":"2009-02-17","legal_status":"Granted"} US7491736B2 17 Feb, 2009 Granted 10 Mar, 2025
{"application_id":"71346","ingredient":"REVEFENACIN","trade_name":"YUPELRI","family_id":"a6fff3d938544a1ba92e","publication_number":"US10343995B2","cleaned_patent_number":"10343995","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2025-03-10","publication_date":"2019-07-09","legal_status":"Expired"} US10343995B2 09 Jul, 2019 Expired 10 Mar, 2025
{"application_id":"71339","ingredient":"REVEFENACIN","trade_name":"YUPELRI","family_id":"a6fff3d938544a1ba92e","publication_number":"US8273894B2","cleaned_patent_number":"8273894","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2025-03-10","publication_date":"2012-09-25","legal_status":"Patented case"} US8273894B2 Formulation 25 Sep, 2012 Patented case 10 Mar, 2025
{"application_id":"71337","ingredient":"REVEFENACIN","trade_name":"YUPELRI","family_id":"a6fff3d938544a1ba92e","publication_number":"US8053448B2","cleaned_patent_number":"8053448","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2025-03-10","publication_date":"2011-11-08","legal_status":"Granted"} US8053448B2 08 Nov, 2011 Granted 10 Mar, 2025
{"application_id":"71348","ingredient":"REVEFENACIN","trade_name":"YUPELRI","family_id":"a6fff3d938544a1ba92e","publication_number":"US11247969B2","cleaned_patent_number":"11247969","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2025-03-10","publication_date":"2022-02-15","legal_status":"Expired"} US11247969B2 Formulation 15 Feb, 2022 Expired 10 Mar, 2025
{"application_id":"71336","ingredient":"REVEFENACIN","trade_name":"YUPELRI","family_id":"a6fff3d938544a1ba92e","publication_number":"US8034946B2","cleaned_patent_number":"8034946","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2025-03-10","publication_date":"2011-10-11","legal_status":"Granted"} US8034946B2 Formulation 11 Oct, 2011 Granted 10 Mar, 2025
{"application_id":"71334","ingredient":"REVEFENACIN","trade_name":"YUPELRI","family_id":"a6fff3d938544a1ba92e","publication_number":"US7910608B2","cleaned_patent_number":"7910608","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2025-03-10","publication_date":"2011-03-22","legal_status":"Granted"} US7910608B2 Molecular Formulation 22 Mar, 2011 Granted 10 Mar, 2025
{"application_id":"71332","ingredient":"REVEFENACIN","trade_name":"YUPELRI","family_id":"a6fff3d938544a1ba92e","publication_number":"US7585879B2","cleaned_patent_number":"7585879","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2025-03-10","publication_date":"2009-09-08","legal_status":"Granted"} US7585879B2 Molecular Formulation 08 Sep, 2009 Granted 10 Mar, 2025
{"application_id":"71331","ingredient":"REVEFENACIN","trade_name":"YUPELRI","family_id":"a6fff3d938544a1ba92e","publication_number":"US7550595B2","cleaned_patent_number":"7550595","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2025-03-10","publication_date":"2009-06-23","legal_status":"Granted"} US7550595B2 Formulation 23 Jun, 2009 Granted 10 Mar, 2025
{"application_id":"71330","ingredient":"REVEFENACIN","trade_name":"YUPELRI","family_id":"a6fff3d938544a1ba92e","publication_number":"US7521041B2","cleaned_patent_number":"7521041","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2025-03-10","publication_date":"2009-04-21","legal_status":"Granted"} US7521041B2 21 Apr, 2009 Granted 10 Mar, 2025
{"application_id":"71345","ingredient":"REVEFENACIN","trade_name":"YUPELRI","family_id":"a6fff3d938544a1ba92e","publication_number":"US10106503B2","cleaned_patent_number":"10106503","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2025-03-10","publication_date":"2018-10-23","legal_status":"Expired"} US10106503B2 23 Oct, 2018 Expired 10 Mar, 2025
{"application_id":"71329","ingredient":"REVEFENACIN","trade_name":"YUPELRI","family_id":"a6fff3d938544a1ba92e","publication_number":"US7288657B2","cleaned_patent_number":"7288657","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2028-10-31","publication_date":"2007-10-30","legal_status":"Granted"} US7288657B2 Molecular 30 Oct, 2007 Granted 31 Oct, 2028
{"application_id":"71388","ingredient":"REVEFENACIN","trade_name":"YUPELRI","family_id":"5bf840e54ced4641b795","publication_number":"US10550081B2","cleaned_patent_number":"10550081","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2030-07-14","publication_date":"2020-02-04","legal_status":"Granted"} US10550081B2 Molecular 04 Feb, 2020 Granted 14 Jul, 2030
{"application_id":"115710","ingredient":"REVEFENACIN","trade_name":"YUPELRI","family_id":"5bf840e54ced4641b795","publication_number":"US11858898B2","cleaned_patent_number":"11858898","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2030-07-14","publication_date":"2024-01-02","legal_status":"Granted"} US11858898B2 Molecular Formulation 02 Jan, 2024 Granted 14 Jul, 2030
{"application_id":"71389","ingredient":"REVEFENACIN","trade_name":"YUPELRI","family_id":"5bf840e54ced4641b795","publication_number":"US11691948B2","cleaned_patent_number":"11691948","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2030-07-14","publication_date":"2023-07-04","legal_status":"Granted"} US11691948B2 Formulation 04 Jul, 2023 Granted 14 Jul, 2030
{"application_id":"71386","ingredient":"REVEFENACIN","trade_name":"YUPELRI","family_id":"5bf840e54ced4641b795","publication_number":"US9765028B2","cleaned_patent_number":"9765028","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2030-07-14","publication_date":"2017-09-19","legal_status":"Granted"} US9765028B2 Molecular 19 Sep, 2017 Granted 14 Jul, 2030
{"application_id":"71352","ingredient":"REVEFENACIN","trade_name":"YUPELRI","family_id":"5bf840e54ced4641b795","publication_number":"US11008289B2","cleaned_patent_number":"11008289","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2030-07-14","publication_date":"2021-05-18","legal_status":"Patented case"} US11008289B2 18 May, 2021 Patented case 14 Jul, 2030
{"application_id":"71382","ingredient":"REVEFENACIN","trade_name":"YUPELRI","family_id":"5bf840e54ced4641b795","publication_number":"US8541451B2","cleaned_patent_number":"8541451","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-08-25","publication_date":"2013-09-24","legal_status":"Granted"} US8541451B2 Molecular 24 Sep, 2013 Granted 25 Aug, 2031
{"application_id":"164430","ingredient":"REVEFENACIN","trade_name":"YUPELRI","family_id":"a851c30f98694ec598de","publication_number":"US12285417B2","cleaned_patent_number":"12285417","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2039-08-29","publication_date":"2025-04-29","legal_status":"Granted"} US12285417B2 29 Apr, 2025 Granted 29 Aug, 2039
{"application_id":"124163","ingredient":"REVEFENACIN","trade_name":"YUPELRI","family_id":"a851c30f98694ec598de","publication_number":"US12048692B2","cleaned_patent_number":"12048692","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2039-08-29","publication_date":"2024-07-30","legal_status":"Granted"} US12048692B2 30 Jul, 2024 Granted 29 Aug, 2039
{"application_id":"108549","ingredient":"REVEFENACIN","trade_name":"YUPELRI","family_id":"a851c30f98694ec598de","publication_number":"US11484531B2","cleaned_patent_number":"11484531","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2039-10-23","publication_date":"2022-11-01","legal_status":"Granted"} US11484531B2 01 Nov, 2022 Granted 23 Oct, 2039

Recent Clinical Trials

Latest clinical trials and research studies for this ingredient

NCT ID Title Status Phase Conditions Start Date Completion Date

API Suppliers/Manufacturer (Branded/Generic companies)

Manufacturing Locations

View Complete Supplier List

Unlock access to all suppliers of Revefenacin

✓ Access a comprehensive list of global suppliers
✓ Get information on each supplier
Unlock Suppliers

Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.

GreyB © 2025 Elixir. All rights reserved.